Trend/momentum: Bearish bias. MACD histogram is negative (-0.0137) and expanding lower, indicating strengthening downside momentum.
RSI(6) at ~39: weak/soft momentum (not deeply oversold), so there’s room for further downside before a typical oversold bounce.
Moving averages: Converging MAs suggest consolidation, but with MACD bearish this consolidation is resolving downward rather than upward.
Key levels: Pivot 1.208 is overhead (price below pivot = bearish). Immediate support S1 ~1.09 (very close). If S1 fails, next support S2 ~1.016. Resistance levels to reclaim: 1.326 (R1) then 1.40 (R2).
Pattern-based short-term odds: modest positive skew is shown for next week/month, but the expected magnitude is small versus nearby downside to S2 if support breaks.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Open interest is call-heavy (calls 2234 vs puts 205), producing an extremely low put/call OI ratio (0.09) → structurally bullish positioning.
However, today’s options volume is 0 (calls 0, puts 0) → sentiment is not being actively expressed today; OI may be stale positioning.
Volatility: 30D IV ~220.9% vs historical vol ~78.4% → options are pricing very high uncertainty; this often coincides with dilution/financing risk in microcaps and makes directionally buying shares less attractive without a catalyst.
IV percentile ~54 and IV rank ~25.6: elevated absolute IV, but not at extreme highs relative to its own history.
Technical Summary
Sell
5
Buy
10
Positive Catalysts
Technical bounce potential if 1.09 support holds and buyers defend the level.
Gross margin improved to ~53.8% (YoY improvement), showing some operational progress.
Net loss improved YoY (less negative), suggesting cost control relative to last year.
No significant insider or hedge-fund selling pressure flagged in the provided trading trends (both neutral).
Neutral/Negative Catalysts
and MACD is deteriorating; a break below ~1.09 opens a quick path toward ~1.02 support.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: ~$3.44M, down ~5.65% YoY (negative growth).
Net income: ~-$11.02M, improved ~6.71% YoY (loss narrowed, but still materially negative).
EPS: -0.14 (flat YoY per provided data).
Gross margin: ~53.77%, up ~2.67% YoY (margin improvement is a relative positive, but not yet translating into profitability).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, implying limited/unclear Street coverage in this dataset.
Wall Street pro view (based on available data only):
Pros: improving gross margin and slightly improving losses.
Cons: declining revenue, continued sizable losses, and no fresh catalysts; technicals remain bearish below the pivot.
Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is 2 USD with a low forecast of 2 USD and a high forecast of 2 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is 2 USD with a low forecast of 2 USD and a high forecast of 2 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.040
Low
2
Averages
2
High
2
Current: 1.040
Low
2
Averages
2
High
2
Lake Street
Buy
maintain
$2
AI Analysis
2025-08-14
Reason
Lake Street
Price Target
$2
AI Analysis
2025-08-14
maintain
Buy
Reason
Lake Street raised the firm's price target on Hyperfine to $2 from $1.50 and keeps a Buy rating on the shares after the company reported Q2 results and reiterated 2025 guidance for 10%-20% revenue growth. The firm believes a growth inflection supports multiple expansion, the analyst tells investors in a post-earnings note.
B. Riley
Yuan Zhi
Buy
maintain
$1
2025-06-03
Reason
B. Riley
Yuan Zhi
Price Target
$1
2025-06-03
maintain
Buy
Reason
B. Riley analyst Yuan Zhi reiterates a Buy rating on Hyperfine with a $1 price target after the company's premium Swoop received FDA 510k approval weeks ahead of schedule. The new next-generation MRI system includes a new scanner and Optive artificial intelligence software, producing the highest level of image quality and uniformity, the analyst tells investors in a research note. The firm says Hyperfine kept the hardware development confidential up until yesterday, so it is likely not on many investor radars. Riley points out the trading volume of Hyperfine on Monday was greater than 100M shares, more than the entire float. This trading abnormality could be related to trading algorithms catching the keyword "AI," the firm contends.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HYPR
